Science Explorer Back to mapMap

Most cited papers from The Christie NHS Foundation Trust

What are the most cited papers from The Christie NHS Foundation Trust?

The most cited paper from The Christie NHS Foundation Trust is "Improved Survival with Ipilimumab in Patients with Metastatic Melanoma" (Frank Stephen Hodi et al., 2010), with 15,337 citations. Next come "Perioperative Chemotherapy versus Surgery Alone for Resectable Gastroesophageal Cancer" (6,432) and "Pembrolizumab versus Ipilimumab in Advanced Melanoma" (5,968).

Showing 50 of 60 papers. Every paper with more than 1,155 citations is listed.

Most cited papers, sortable by citations and release date
#Paper
1 Improved Survival with Ipilimumab in Patients with Metastatic Melanoma Frank Stephen Hodi et al. · New England Journal of Medicine Open access 5 Jun 2010 15,337
2 Perioperative Chemotherapy versus Surgery Alone for Resectable Gastroesophageal Cancer David Cunningham, William Allum, Sally Patricia Stenning et al. · New England Journal of Medicine 6 Jul 2006 6,432
3 Pembrolizumab versus Ipilimumab in Advanced Melanoma Caroline Robert et al. · New England Journal of Medicine Open access 19 Apr 2015 5,968
4 Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer Juan W. Valle, Harpreet Singh Wasan, Daniel H. Palmer et al. · New England Journal of Medicine Open access 7 Apr 2010 4,489
5 Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma Brian I. Rini et al. · New England Journal of Medicine Open access 16 Feb 2019 3,488
6 Crizotinib versus Chemotherapy in Advanced ALK -Positive Lung Cancer Alice Tsang Shaw et al. · New England Journal of Medicine Open access Jun 2013 3,429
7 Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation Mark E. Robson, Seock‐Ah Im, Elżbieta Senkus et al. · New England Journal of Medicine Open access 4 Jun 2017 3,322
8 Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib Caroline Robert et al. · New England Journal of Medicine Open access 16 Nov 2014 2,718
9 Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial Jeffrey S. Weber et al. · The Lancet Oncology 23 Mar 2015 2,696
10 Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Silvia Novello, Fabrice Barlési, Raffaele Califano et al. · Annals of Oncology Open access Sep 2016 2,650
11 Pancreatic cancer Jonathan D. Mizrahi, Rishi Surana, Juan W. Valle et al. · The Lancet Jun 2020 2,586
12 Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors Éric Raymond, Laëtitia Dahan, Jean‐Luc Raoul et al. · New England Journal of Medicine 9 Feb 2011 2,567
13 Cholangiocarcinoma 2020: the next horizon in mechanisms and management Jesús M. Bañales et al. · Nature Reviews Gastroenterology & Hepatology ReviewOpen access 30 Jun 2020 2,543
14 Tracking the Evolution of Non–Small-Cell Lung Cancer Mariam Jamal‐Hanjani et al. · New England Journal of Medicine Open access 26 Apr 2017 2,501
15 Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer Anthony Howell, Jack M. Cuzick, Michael Baum et al. · The Lancet 2005 2,295
16 AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer Darren A.E. Cross et al. · Cancer Discovery Open access 4 Jun 2014 2,276
17 DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer Joaquı́n Mateo et al. · New England Journal of Medicine Open access 28 Oct 2015 2,220
18 Pathogenesis and clinical features of psoriasis Christopher E.M. Griffiths, Jonathan NWN Barker · The Lancet Jul 2007 2,164
19 AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer Pasi Antero Janne, James Chih‐Hsin Yang, Dong‐Wan Kim et al. · New England Journal of Medicine Open access 29 Apr 2015 2,135
20 Conditions controlling the proliferation of haemopoietic stem cells in vitro T. M. Dexter, Terence Allen, L. G. Lajtha · Journal of Cellular Physiology Jun 1977 2,117
21 Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer) Nick Thatcher, Alex Y. Chang, Purvish Mahendra Parikh et al. · The Lancet Oct 2005 2,097
22 Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial Nicholas David James et al. · The Lancet Open access 21 Dec 2015 1,985
23 Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution Christopher Abbosh et al. · Nature Open access104 authors 25 Apr 2017 1,978
24 Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial John P. Neoptolemos et al. · The Lancet Open access 24 Jan 2017 1,953
25 Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma Robert John Motzer et al. · New England Journal of Medicine Open access 21 Aug 2013 1,936
26 Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma Alexander M.M. Eggermont et al. · New England Journal of Medicine Open access 15 Apr 2018 1,906
27 Ovarian cancer Gordon C. Jayson, Elise C. Kohn, Henry Charles Kitchener et al. · The Lancet 21 Apr 2014 1,893
28 Stem cells: attributes, cycles, spirals, pitfalls and uncertainties. Lessons for and from the crypt Christopher S. Potten, Markus W. Loeffler · Development Dec 1990 1,818
29 Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy Nicholas David James et al. · New England Journal of Medicine Open access 3 Jun 2017 1,806
30 The antioxidant action of N-acetylcysteine: Its reaction with hydrogen peroxide, hydroxyl radical, superoxide, and hypochlorous acid Okezie I. Aruoma, Barry B. Halliwell, Brigid M. Hoey et al. · Free Radical Biology and Medicine 1989 1,780
31 A Randomized Trial of Exemestane after Two to Three Years of Tamoxifen Therapy in Postmenopausal Women with Primary Breast Cancer R. Charles Coombes et al. · New England Journal of Medicine Open access 10 Mar 2004 1,773
32 Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial Robert Louis Coleman et al. · The Lancet Open access117 authors 12 Sep 2017 1,729
33 Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial Christopher M. Nutting, James P. Morden, Kevin Joseph Harrington et al. · The Lancet Oncology Open access 14 Jan 2011 1,721
34 Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma Michael Wang et al. · New England Journal of Medicine Open access 19 Jun 2013 1,710
35 Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis Andrew G. Renehan, Marcel Zwahlen, Christoph Erwin Minder et al. · The Lancet Review Apr 2004 1,702
36 Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study Jong‐Mu Sun et al. · The Lancet Open access Aug 2021 1,679
37 Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial Andrew N.J. Tutt, Mark E. Robson, Judy Ellen Garber et al. · The Lancet Jul 2010 1,660
38 Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia John C. Byrd et al. · New England Journal of Medicine Open access 31 May 2014 1,649
39 Small-cell lung cancer Charles M. Rudin, Elisabeth M. Brambilla, Corinne Faivre Finn et al. · Nature Reviews Disease Primers ReviewOpen access 14 Jan 2021 1,632
40 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial Ian Smith et al. · The Lancet 2007 1,521
41 Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer Scott Kopetz et al. · New England Journal of Medicine Open access 30 Sep 2019 1,500
42 The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials Joanne Haviland, John R. Owen, John A. Dewar et al. · The Lancet Oncology Open access 18 Sep 2013 1,479
43 Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial George D. Demetri et al. · The Lancet Open access 21 Nov 2012 1,428
44 Adjuvant Chemotherapy With Fluorouracil Plus Folinic Acid vs Gemcitabine Following Pancreatic Cancer Resection John P. Neoptolemos et al. · JAMA 7 Sep 2010 1,403
45 Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer David R. Spigel et al. · Journal of Clinical Oncology Open access 2 Feb 2022 1,400
46 Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial David Paul Dearnaley et al. · The Lancet Oncology Open access 22 Jun 2016 1,350
47 Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial Kohei Shitara et al. · The Lancet Open access158 authors 4 Jun 2018 1,338
48 Malignant peripheral nerve sheath tumours in neurofibromatosis 1 D. Gareth Evans, M E Baser, J McGaughran et al. · Journal of Medical Genetics Open access May 2002 1,297
49 Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial Christopher Parker et al. · The Lancet Open access 21 Oct 2018 1,289
50 Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study James C. Yao et al. · The Lancet Open access 17 Dec 2015 1,288

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.